AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24013578 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of retinal tacks using custom-built titanium alloy tacks, mechanically removed after prolonged implantation (up to 19 months).
Number of subjects: 4
Study 24013904 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 650 mg/m(2) twice daily and everolimus 5 mg twice daily
Number of subjects: 47
Study 24014245 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at maximum planned dose (MPD)
Number of subjects: 52
Study 24014245 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in bortezomib-refractory patients
Number of subjects: 52
Study 24014245 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in lenalidomide-refractory patients
Number of subjects: 52
Study 24014245 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at MPD
Number of subjects: 52
Study 24014245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to CRd
Number of subjects: 52
Study 24014509 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24014659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pulses
Number of subjects: 554
Study 24014882 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n = 2926)
Number of subjects: 5838
Study 24015953 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone in 2 ml saline (treatment group)
Number of subjects: 152
Study 24015953 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (placebo group)
Number of subjects: 152
Study 24016493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD and CAD
Number of subjects: 3300
Study 24016493 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 6, 12, 24, 36, 48, and 60 months
Number of subjects: 3300
Study 24018147 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound-guided RFVTA
Number of subjects: 135
Study 24018545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 24018545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24018835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 2515
Study 24018835 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2515
Study 24019004 — intervention group
Group type: EXPERIMENTAL
Intervention: Verified spider bites (Cheiracanthium punctorium, Zoropsis spinimana, Amaurobius ferox, Tegenaria atrica, Malthonica ferruginea)
Number of subjects: 19
Study 24019004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheiracanthium punctorium
Number of subjects: 19
Study 24019004 — intervention group
Group type: EXPERIMENTAL
Intervention: General spider bites in Switzerland
Number of subjects: 19
Study 24019130 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit study
Number of subjects: 12134
Study 24019130 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit study without patient feedback
Number of subjects: 12134
Study 24019244 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO >15.8 ppb
Number of subjects: 3612
Study 24019244 — intervention group
Group type: EXPERIMENTAL
Intervention: Rint >175.4%
Number of subjects: 3612
Study 24019244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function parameters and FeNO interpretation
Number of subjects: 3612
Study 24019397 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizer in patients with AMI
Number of subjects: 2188
Study 24019397 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 extensive metabolizer in patients with AMI
Number of subjects: 2188
Study 24019397 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizer in patients with stable angina
Number of subjects: 2188
Study 24019397 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 intermediate metabolizer in patients with AMI
Number of subjects: 2188
Study 24019397 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 extensive metabolizer in patients with stable angina
Number of subjects: 2188
Study 24019544 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg plus bortezomib 1.3 mg/m(2) (MTD) in the escalation phase
Number of subjects: 62
Study 24019544 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib with dexamethasone in the expansion phase
Number of subjects: 62
Study 24019544 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib in the escalation phase
Number of subjects: 62
Study 24019544 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib in the expansion phase
Number of subjects: 62
Study 24019544 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib in bortezomib-refractory patients
Number of subjects: 62
Study 24021693 — intervention group
Group type: EXPERIMENTAL
Intervention: cCTA-guided triage
Number of subjects: 368
Study 24021693 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 368
Study 24021766 — intervention group
Group type: EXPERIMENTAL
Intervention: Engager transapical valve system
Number of subjects: 61
Study 24021910 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided radiofrequency volumetric thermal ablation
Number of subjects: 135
Study 24021910 — intervention group
Group type: COMPARATOR
Intervention: Site CE-MRI
Number of subjects: 135
Study 24021910 — intervention group
Group type: COMPARATOR
Intervention: Central reader CE-MRI
Number of subjects: 135
Study 24021910 — intervention group
Group type: COMPARATOR
Intervention: TVUS
Number of subjects: 135
Study 24022390 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 900 mg daily in three divided doses (control)
Number of subjects: 15
Study 24022390 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised hypnotherapy
Number of subjects: 15
Study 24022986 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-scale (GS) and power Doppler (PD) ultrasound
Number of subjects: 49
Study 24022986 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 49
Study 24023466 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2 g/day)
Number of subjects: 70
Study 24023466 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 70
Study 24023652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion test
Number of subjects: 17
Study 24023652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion test in patients with good hypoglycaemia awareness
Number of subjects: 17
Study 24023652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion test in patients with poor hypoglycaemia awareness
Number of subjects: 17
Study 24023791 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP2 based rapid diagnostic test (RDT)
Number of subjects: 3890
Study 24024534 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (flexibly dosed at 400-800 mg/day, with options to reduce to 200 mg/day based on tolerability)
Number of subjects: 381
Study 24025234 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVent-ASV™
Number of subjects: 100
Study 24025234 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVent-ASV™ in passive patients
Number of subjects: 100
Study 24025234 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVent-ASV™ in passive ARDS patients
Number of subjects: 100
Study 24025627 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV-TAS2R38 mRNA expression
Number of subjects: 22
Study 24025627 — intervention group
Group type: COMPARATOR
Intervention: Control solutions (carrot juice, NaCl, caffeine, urea)
Number of subjects: 22
Study 24025631 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion measurement
Number of subjects: 1656
Study 24025631 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fruit and vegetable intake
Number of subjects: 1656
Study 24025631 — intervention group
Group type: COMPARATOR
Intervention: Comparison of potassium excretion by race
Number of subjects: 1656
Study 24025631 — intervention group
Group type: COMPARATOR
Intervention: Comparison of potassium excretion by education level
Number of subjects: 1656
Study 24025631 — intervention group
Group type: COMPARATOR
Intervention: Comparison of potassium excretion by income level
Number of subjects: 1656
Study 24025631 — intervention group
Group type: COMPARATOR
Intervention: Access to fresh produce
Number of subjects: 1656
Study 24025700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and vemurafenib
Number of subjects: 1
Study 24025700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroids
Number of subjects: 1
Study 24027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal phenotype and diet
Number of subjects: 52
Study 24027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk oligosaccharide concentration
Number of subjects: 52
Study 24027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Total concentration of milk oligosaccharides
Number of subjects: 52
Study 24027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of interrelations between milk sugars
Number of subjects: 52
Study 24028306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs (diuretic, ACE inhibitors, β-adrenergic blocking agent, calcium channel blocking agent) if BP >130/80 mmHg.
Number of subjects: 78
Study 24028306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs.
Number of subjects: 78
Study 24028564 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive TV parenting practices
Number of subjects: 83
Study 24028564 — intervention group
Group type: EXPERIMENTAL
Intervention: PA logistic support parenting practices
Number of subjects: 83
Study 24028564 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased availability of screen-media equipment in the child's bedroom
Number of subjects: 83
Study 24028677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (75 or 150 mg in a pre-filled syringe) at 2 or 4 week intervals for 24 weeks
Number of subjects: 155
Study 24028745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 371
Study 24028745 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 371
Study 24028745 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 371
Study 24028745 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 371
Study 24028749 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant placed within 15 min of mifepristone administration
Number of subjects: 20
Study 24029408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf p52(-)/p36(-) GAP sporozoites via infected Anopheles mosquito bite (5-bite exposure followed by 200-bite exposure)
Number of subjects: 6
Study 24029408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf p52(-)/p36(-) GAP sporozoites
Number of subjects: 6
Study 24030098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily on days 1-21 every 28 days until progressive disease or intolerability
Number of subjects: 57
Study 24030379 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived CD19.CAR virus-specific T cells (CD19.CAR-VSTs)
Number of subjects: 8
Study 24030617 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24030685 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day
Number of subjects: 45
Study 24030879 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with sulfadoxine/pyrimethamine (SP) given twice during pregnancy
Number of subjects: 0
Study 24030879 — intervention group
Group type: EXPERIMENTAL
Intervention: ITNs alone
Number of subjects: 0
Study 24030879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention with both ITNs and IPTp-SP
Number of subjects: 0
Study 24030879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of IPTp-SP
Number of subjects: 0
Study 24030879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of ITNs
Number of subjects: 0
Study 24030879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of combined intervention IPTp-SP + ITNs
Number of subjects: 0
Study 24030917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Number of subjects: 30
Study 24030918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 30 or 40 mg/m² intravenously on day 1; dexamethasone 40 mg orally on days 1-4; lenalidomide 25 mg orally on days 1-21, administered every 28 days
Number of subjects: 57
Study 24030918 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 57
Study 24030918 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with lenalidomide
Number of subjects: 57
Study 24030928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with protease inhibitors (PIs)
Number of subjects: 52
Study 24030928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with efavirenz (EFV)
Number of subjects: 52
Study 24030928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) with efavirenz (EFV)
Number of subjects: 52
Study 24030928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with nevirapine (NVP)
Number of subjects: 52
Study 24032456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg IV on Day 1, followed by seven weekly IV infusions of 1000 mg.
Number of subjects: 81
Study 24033249 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep problems
Number of subjects: 314
Study 24033923 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant C3a/C5a
Number of subjects: 0
Study 24033923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological C5aR blockade
Number of subjects: 0
Study 24033923 — intervention group
Group type: EXPERIMENTAL
Intervention: DC C3a/C5a production lowered by siRNA knockdown of DC C3
Number of subjects: 0
Study 24033923 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulating DC expression of decay-accelerating factor
Number of subjects: 0
Study 24034562 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy combined with weekly gemcitabine and adjuvant gemcitabine
Number of subjects: 0
Study 24035405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab 15 mg/kg intravenously once every 90 days until progressive disease or severe toxicity
Number of subjects: 29
Study 24035405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 29
Study 24035447 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-BAND AP System (LBAP)
Number of subjects: 1106
Study 24035535 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cannabis cues
Number of subjects: 16
Study 24035558 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro ring-stage survival assay (RSA) on 0-3 h ring-stage parasites
Number of subjects: 30
Study 24035558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-vivo RSA
Number of subjects: 30
Study 24036246 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 24037083 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg orally once daily
Number of subjects: 41
Study 24037083 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 41
Study 24037550 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (Zostavax)
Number of subjects: 10
Study 24037550 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects ≥ age 50 years)
Number of subjects: 10
Study 24037801 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine wafers (CW)
Number of subjects: 59
Study 24037866 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-directed treatment (ComDT) added to health facility (HF) approach
Number of subjects: 0
Study 24037866 — intervention group
Group type: COMPARATOR
Intervention: Health facility (HF) approach alone
Number of subjects: 0
Study 24037867 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 613
Study 24037867 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 613
Study 24037867 — intervention group
Group type: COMPARATOR
Intervention: Non-recommended antimalarials
Number of subjects: 613
Study 24037867 — intervention group
Group type: COMPARATOR
Intervention: Laboratory diagnosis
Number of subjects: 613
Study 24038364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine/pyrimethamine (IPTi-SP)
Number of subjects: 29000
Study 24038364 — intervention group
Group type: COMPARATOR
Intervention: Comparison areas (not receiving IPTi-SP)
Number of subjects: 29000
Study 24039230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic rhinosinusitis (CRS)
Number of subjects: 70000000
Study 24039230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory disease process
Number of subjects: 70000000
Study 24039230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep physiology regulation
Number of subjects: 70000000
Study 24040920 — intervention group
Group type: EXPERIMENTAL
Intervention: Information from the general practitioner about high cholesterol and risk of cardiovascular disease
Number of subjects: 14
Study 24040920 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mindset as a strategy to lower risk of high cholesterol
Number of subjects: 14
Study 24041790 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 60
Study 24041790 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women with noncalcified coronary plaque
Number of subjects: 60
Study 24042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism following a restricted diet
Number of subjects: 69
Study 24042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism not following a restricted diet
Number of subjects: 69
Study 24042076 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (TYP)
Number of subjects: 69
Study 24042076 — intervention group
Group type: COMPARATOR
Intervention: Children with developmental delay
Number of subjects: 69
Study 24042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism (AUT)
Number of subjects: 69
Study 24042076 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism (AUT) with intentional diet restrictions
Number of subjects: 69
Study 24042386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 24042540 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT at 3 months
Number of subjects: 89
Study 24042540 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 89
Study 24042540 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of being free of local recurrence
Number of subjects: 89
Study 24043379 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle assembly
Number of subjects: 0
Study 24043379 — intervention group
Group type: COMPARATOR
Intervention: Traditional catheter assembly
Number of subjects: 0
Study 24044794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac comorbidity
Number of subjects: 259
Study 24044794 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with cardiac comorbidity and other factors
Number of subjects: 259
Study 24044880 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from family and friends
Number of subjects: 247
Study 24044880 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-related attitudinal variables
Number of subjects: 247
Study 24044880 — intervention group
Group type: EXPERIMENTAL
Intervention: General social support (ISEL)
Number of subjects: 247
Study 24044880 — intervention group
Group type: EXPERIMENTAL
Intervention: SSQ scores
Number of subjects: 247
Study 24045453 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total fundoplication (LTF)
Number of subjects: 188
Study 24045500 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24045608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amantadine sulfate 200 mg
Number of subjects: 6
Study 24046475 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal optimization strategies
Number of subjects: 0
Study 24046475 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 24047338 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative volume above higher SUV (80%)
Number of subjects: 220
Study 24047338 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic tumor volume (MTV) based on volumes above SUV of 3, 40% and 50% of maximum SUV
Number of subjects: 220
Study 24047338 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum and peak SUV
Number of subjects: 220
Study 24047768 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning left-sided double-lumen tubes (DLTs) using minimum PIP differences
Number of subjects: 102
Study 24047768 — intervention group
Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 102
Study 24047918 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the 2006 American Heart Association Diet and Lifestyle Recommendations (AHA-DLR)
Number of subjects: 933
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERSALT equations with morning specimens
Number of subjects: 407
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERSALT equations with afternoon specimens
Number of subjects: 407
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERSALT equations with evening specimens
Number of subjects: 407
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaka equations with overnight specimens
Number of subjects: 407
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mage equations with overnight specimens
Number of subjects: 407
Study 24047921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaka equations among females
Number of subjects: 407